Executive Summary
This $6.08B batch of mega contracts is dominated by Lockheed Martin's $2.87B NASA space vehicle award (47% of total), underscoring persistent U.S. space spending despite historical timelines. Emerging bullish signals in nuclear energy via General Matter's $900M DOE HALEU production deal and healthcare IT via Optum's $724M VA order highlight growth in strategic sectors.
IT/defense primes like Leidos, ManTech, Palantir show $600M+ obligations with $1.4B options potential, though $0 outlays across most signal funding lags; prioritize monitoring option exercises for 50%+ upside.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Mega Contracts Monitor ($100M+) digest from March 05, 2026.
Investment Signals (4)
- Lockheed Martin NASA dominance (HIGH)▲
47% of total value in $2.87B space components contract reinforces Lockheed's entrenched NASA positioning.
- HALEU nuclear capacity ramp (HIGH)▲
$900M DOE award to small biz General Matter for 10-year HALEU UF6 production establishes domestic supply chain play.
- Healthcare IT backlog growth (MEDIUM)▲
$869M combined in Optum VA managed care and GD CMS HIGLAS hosting signals steady fed healthcare digitization spend.
- Defense IT primes scaling (HIGH)▲
Leidos, ManTech (x2), Palantir secure $500M+ obligations with $1.3B options for Army/DHS/GSA networks and case mgmt.
Risk Flags (3)
- Execution [HIGH RISK]▼
$0 outlayed on 11/12 contracts despite $6B obligations, plus ended performance periods on 6 (pre-2014), flags cash flow delays/data lags.
- Market [MEDIUM RISK]▼
Firm fixed price on 5 contracts ($1.5B total: Optum, Pernix, ManTech State, Palantir, Pernix) exposes to cost inflation overruns over 1-10yr spans.
- Competitive [MEDIUM RISK]▼
High subawards (e.g., $177M/119 on GD, $134M/39 on Leidos, $112M/34 on ManTech) erode prime margins via subcontractor dependencies.
Opportunities (3)
- ◆
$2.3B unexercised options across batch (e.g., $507M ManTech GSA, $208M Leidos GSA, $235M General Matter DOE).
- ◆
Small biz wins on $1.3B mega deals (General Matter HALEU, Pernix State construction) signal scaling path for niche players.
- ◆
Potential extensions add 2-5yrs revenue (e.g., GD to 2031, Leidos to 2029, ManTech to 2028).
Sector Themes (3)
- ◆
NASA awards total $3.41B (56% batch: Lockheed $2.87B, Hamilton/DynCorp/Amentum), mostly historical but with options.
- ◆
DOE $900M HALEU deal amid nuclear revival; contrasts legacy space.
- ◆
$1.1B in IT/engineering delivery orders (GSA/DHS/State: Leidos, ManTech, Palantir, GD).
Watch List (3)
- 👁
{"entity"=>"Lockheed Martin", "reason"=>"Single largest obligation at 47% total; $52M options + extension potential despite ended period.", "trigger"=>"outlay >$0 or new NASA mods"}
- 👁
{"entity"=>"General Matter, Inc.", "reason"=>"New $900M/10yr HALEU small biz win with $235M options; zero outlay start.", "trigger"=>"DOE funding release or HALEU policy shifts"}
- 👁
{"entity"=>"ManTech International", "reason"=>"$269M dual awards with $650M+ options; high subawards pressure margins.", "trigger"=>"GSA option exercises"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 12 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Mega Contracts Monitor ($100M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals